Standigm and Excelra Announce Strategic Collaboration to Advance AI-Driven Drug Discovery

Hyderabad, India and Seoul, South Korea, Sept. 15, 2020 /PRNewswire/ -- A global enterprise in data science and data analyticsExcelraToday, it was announced that a partnership has been reached with Standigm, Inc., which uses artificial intelligence (AI) technology for drug discovery and development.

Under the collaboration agreement, Excelra will provide its intelligent small-molecule medicinal chemistry platform to Standigm, Inc.GOSTARThe GOSTAR platform provides rich information on over 8 million compounds, manually curated from 3 million patents and 200,000 journal articles. The database contains more than 28 million SAR-related data points. This well-structured relational database supports numerous applications across different stages of the drug discovery and development lifecycle, aiding in target validation, hit identification, early lead recognition, and optimization.

Standigm Inc.PlatformTeam LeaderHanjo KimIndication:“For AI-based drug discovery companies, high-quality SAR data is crucial. Our platform technology, Standigm BEST”^™、Standigm ASK^™and Standigm Insight^™“Integrating large datasets to generate innovative ideas, including the discovery of new targets, development of predictive models, and design of novel lead compound series. I believe GOSTAR will accelerate this process.”

ExcelraChemical Protective SuitChief Financial OfficerRaveendra DayamIndicates:GOSTAR is the largest experimentally determined source of information on interactions between millions of small molecules and most potential drug targets. The platform provides a comprehensive overview of millions of compounds, linking chemical structures to biological, pharmacological, and therapeutic activities. These datasets are central to AI/ML-driven drug discovery projects, supporting the development of new drug candidates.